Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

Nuclear Medicine Communications

Volumn 34, Issue 10, 2013, Pages 946-952

  González Barca, Eva ^a   Canales, Miguel ^e   Cortés, Montse ^b   Vidal, M Jesus ^g   Salar, Antonio ^c   Oriol, Albert ^d   Bargay, Joan ^h   Bello, José L ⁱ   Sánchez, José J ^j   Tomás, José F ^f   Donato, Eva ^k   Ferrer, Secundino ^l   Caballero, Dolores ^m  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b Institut of Diagnosis by Image (IDI)   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f MD ANDERSON CANCER CENTER   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h Hospital Sont Llatzer   (Spain)

ⁱ Instituto de Salud Carlos III   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k Castellon University General Hospital   (Spain)

^l HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^m HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

diffuse large B cell lymphoma; pegfilgrastim; PET; R CHOP

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSE DENSIFICATION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; WHOLE BODY PET;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISONE; RECOMBINANT PROTEINS; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE; VINCRISTINE; YOUNG ADULT;

EID: 84883654208     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328363c695     Document Type: Article

References (31)

1. Armitage JO, Weisenburger DD New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-2795. (Pubitemid 28363044)
2. Coiffier B, Lepage E, Briere J., Herbrecht R, Tilly H, Bouabdallah R., et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242. (Pubitemid 34438862)
3. Feugier P, Van HA, Sebban C, Solal-Celigny P, Bouabdallah R., Ferme C, et al Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-4126. (Pubitemid 46211317)
4. Pfreundschuh M, Trumper L, Osterborg A., Pettengell R, Trneny M, Imrie K., et al CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.
5. Pfreundschuh M, Trumper L, Kloess M., Schmits R, Feller AC, Rube C, et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104:634-641. (Pubitemid 38970554)
6. Pfreundschuh M, Trumper L, Kloess M., Schmits R, Feller AC, Rudolph C, et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104:626-633. (Pubitemid 38970553)
7. Shipp MA. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
8. Juweid ME, Stroobants S, Hoekstra O.S., Mottaghy FM, Dietlein M, Guermazi A, et al Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-578. (Pubitemid 350002965)
9. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. (Pubitemid 350002966)
10. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613-618. (Pubitemid 30450941)
11. Spaepen K, Stroobants S, Dupont P., Vandenberghe P, Thomas J, de Groot T, et al Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1356-1363.
12. Kostakoglu L, Coleman M, Leonard J.P., Kuji I., Zoe H, Goldsmith SJ PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43:1018-1027. (Pubitemid 34847924)
13. 18 F]Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106:1376-1381. (Pubitemid 41129604)
14. Mikhaeel NG, Hutchings M, Fields P.A., O'Doherty MJ, Timothy AR FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16:1514-1523. (Pubitemid 41222425)
15. Dupuis J, Itti E, Rahmouni A., Hemery F, Gisselbrecht C, Lin C., et al Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 2009; 20:503-507.
16. Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M., Conti PS Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009; 14 (SUPPL. 2):30-40.
17. González-Barca E, Canales MA, Salar A, Ferrer S, Bargay J, Gardella S, et al. Final results of compliance, safety and eficacy of first line treatment with 6 cycles of R-CHOP-14 and pegfilgastrim in large B-cell lymphoma: multicentric prospective study. LII National Meeting Sapnish Hematology Association (AEHH). Las palmas de Gran Canaria 2010 [abstract CO-24]. Haematologica 2010; 95:10.
18. Oken MM, Creech RH, Tormey D.C., Horton J., Davis TE, McFadden ET, et al Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655. (Pubitemid 13149996)
19. Aapro MS, Bohlius J, Cameron D.A., Lago LD, Donnelly JP, Kearney N, et al 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47:8-32.
20. Cheson BD, Horning SJ, Coiffier B, Shipp M.A., Fisher RI, Connors JM, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244.
21. Pregno P, Chiappella A, Bello M., Botto B, Ferrero S, Franceschetti S., et al Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012; 119:2066-2073.
22. Horning SJ, Juweid ME, Schoder H, Wiseman G., McMillan A, Swinnen LJ, et al Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010; 115:775-777, quiz 918.
23. Thomas A, Gingrich RD, Smith B.J., Jacobus L., Ristow K, Allmer C, et al 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports. Leuk Lymphoma 2010; 51:439-446.
24. Terasawa T, Lau J, Bardet S., Couturier O, Hotta T, Hutchings M., et al Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27:1906-1914.
25. Han HS, Escalon MP, Hsiao B, Serafini A., Lossos IS High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009; 20:309-318.
26. 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47:885-895. (Pubitemid 46768453)
27. Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C., Iasonos A, Portlock CS, et al Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol 2010; 28:1896-1903.
28. 18F- fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation - where do we stand? Leuk Lymphoma 2009; 50:1753-1756.
29. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S., Julian A, Thieblemont C, et al SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 2011; 118:37-43.
30. 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50:527-533.
31. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48:1626-1632. (Pubitemid 47572710)